VIDAZA Side Effects

6860101-5 |
on Jul 15, 2010 Male patient from GERMANY , 77 years of age, was treated with Vidaza (View Usage). . Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ).

6860098-8 | Alveolitis Allergic, Febrile Neutropenia
Patient was taking Vidaza (View Usage). Patient had the following side effects: alveolitis allergic, febrile neutropenia on Jul 08, 2010 from FRANCE Additional patient health information: Male patient , weighting 165.3 lb, was diagnosed with acute myeloid leukaemia and. Vidaza dosage: . During the same period patient was treated with REVLIMID (View Revlimid Review and Revlimid Label ), GRANOCYTE 34 (View Granocyte 34 Review and Granocyte 34 Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ), CIFLOX (View Ciflox Review and Ciflox Label ). Patient was hospitalized.

6857173-0 | Hypercalcaemia, Renal Failure
Adverse event was reported on Jul 14, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with prophylaxis and. Location: GERMANY , 57 years of age, weighting 152.1 lb, After Vidaza was administered, patient had the following side effects: hypercalcaemia, renal failure. During the same period patient was treated with RED BLOOD CELLS (6 Units) (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYCOTICS (View Antimycotics Review and Antimycotics Label ).

6856602-6 | Diverticulitis, Escherichia Bacteraemia, Neutrophil Count Decreased, White Blood Cell Count Decreased
on Jul 16, 2010 Male patient from UNITED STATES , 48 years of age, weighting 210.5 lb, was diagnosed with sarcoma and was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: diverticulitis, escherichia bacteraemia, neutrophil count decreased, white blood cell count decreased. Vidaza dosage: 250mg Days 1-4 + 15-18 Sq. During the same period patient was treated with TARCEVA (150mg Days 1-28 Po) (View Tarceva Review and Tarceva Label ). Patient was hospitalized.


6837621-2 | Bacteraemia, Blast Cell Count Decreased, Blood Bicarbonate Decreased, Fatigue, Febrile Neutropenia, Haematocrit Decreased, Haemoglobin Decreased, Laboratory Test Interference, Lymphocyte Count Decreased
on Jun 22, 2010 Female patient from AUSTRALIA , 61 years of age, weighting 154.1 lb, was diagnosed with acute myeloid leukaemia and was treated with Vidaza (View Usage). Patient had the following side effects: bacteraemia, blast cell count decreased, blood bicarbonate decreased, fatigue, febrile neutropenia, haematocrit decreased, haemoglobin decreased, laboratory test interference, lymphocyte count decreased. Vidaza dosage: 129 Mg, Injection. During the same period patient was treated with EVEROLIMUS (EVEROLIMUS (INJECTION) (2.5 Mg) (View Everolimus (everolimus (injection) Review and Everolimus (everolimus (injection) Label ), SOTALOL (View Sotalol Review and Sotalol Label ), PROPAX (OXAZEPAM) (View Propax (oxazepam) Review and Propax (oxazepam) Label ), MAXOLON (View Maxolon Review and Maxolon Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ). Patient was hospitalized.

6836751-9 | Deep Vein Thrombosis, Pyrexia, Tachycardia
Patient was taking Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?), pyrexia, tachycardia on Jun 29, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 179.2 lb, was diagnosed with non-small cell lung cancer and. Vidaza dosage: . During the same period patient was treated with LITHIUM CARBONATE (View Lithium Carbonate Review and Lithium Carbonate Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), SEROQUEL (View Seroquel Review and Seroquel Label ), XANAX (View Xanax Review and Xanax Label ), NASACORT (View Nasacort Review and Nasacort Label ), ACTONEL (View Actonel Review and Actonel Label ), ADVAIR DISKUS 100/50 (500/50, 2 Puffs) (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ). Patient was hospitalized.

6835885-2 | Disease Progression
Adverse event was reported on Jul 08, 2010 by a Female patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia, infection prophylaxis and. Location: GERMANY , 74 years of age, Patient experienced the following unwanted or unexpected effects: disease progression. During the same period patient was treated with PLATELETS (View Platelets Review and Platelets Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), MYCOTIC (View Mycotic Review and Mycotic Label ).

6835678-6 | Subdural Haematoma
on Jul 06, 2010 Female patient from UNITED STATES , weighting 205.0 lb, was treated with Vidaza (View Usage). Patient had the following side effects: subdural haematoma. Vidaza dosage: .

6832228-5 | Hip Surgery
on Jun 30, 2010 Female patient from GERMANY , 70 years of age, was diagnosed with acute myeloid leukaemia, antibiotic prophylaxis and was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: hip surgery. Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6831233-2 | Acute Myeloid Leukaemia, Myelodysplastic Syndrome Transformation, Pneumonia
Patient was taking Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, myelodysplastic syndrome transformation, pneumonia (What is pneumonia?) on May 03, 2010 from GERMANY Additional patient health information: Male patient , 81 years of age, . Vidaza dosage: . During the same period patient was treated with ERYTHROCYTES (View Erythrocytes Review and Erythrocytes Label ). Patient was hospitalized.

6826790-6 | Acute Myeloid Leukaemia, Anaemia, Erysipelas, Ileus, Injection Site Erythema, Lung Infection, Mesenteric Occlusion, Myelodysplastic Syndrome Transformation
Adverse event was reported on May 03, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) . Location: GEORGIA , 72 years of age, Patient had the following side effects: acute myeloid leukaemia, anaemia, erysipelas, ileus, injection site erythema, lung infection, mesenteric occlusion, myelodysplastic syndrome transformation.

6826176-4 | Anaemia, Febrile Neutropenia, Thrombocytopenia
on Jul 03, 2010 Male patient from GERMANY , 65 years of age, was diagnosed with acute myeloid leukaemia, prophylaxis and was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: anaemia, febrile neutropenia, thrombocytopenia. Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYCOTICS (View Antimycotics Review and Antimycotics Label ).

6825950-8 | Acute Myeloid Leukaemia, Injection Site Reaction, Myelodysplastic Syndrome Transformation, Nausea
on May 03, 2010 Male patient from GERMANY , 68 years of age, was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, injection site reaction, myelodysplastic syndrome transformation, nausea (What is nausea?). Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS (View Platelets Review and Platelets Label ).

6823228-X |
Patient was taking Vidaza (View Usage). on Jul 05, 2010 from CANADA Additional patient health information: Female patient , 65 years of age, . Vidaza dosage: .

6822485-3 | Anaemia, Febrile Neutropenia, Infection, Thrombocytopenia
Adverse event was reported on Jul 03, 2010 by a Female patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia, prophylaxis and. Location: GERMANY , 72 years of age, After Vidaza was administered, patient had the following side effects: anaemia, febrile neutropenia, infection (What is infection?), thrombocytopenia. During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYKOTICS (View Antimykotics Review and Antimykotics Label ).

6822471-3 | Acute Myeloid Leukaemia, Disease Progression
on Jun 25, 2010 Male patient from GERMANY , 69 years of age, was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, disease progression. Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ).

6822168-X | Escherichia Test Positive, Haemoglobin Decreased, Neutrophil Count Decreased, Pain, Pyrexia
on Jul 07, 2010 Male patient from UNITED STATES , 48 years of age, weighting 210.5 lb, was diagnosed with sarcoma and was treated with Vidaza (View Usage). Patient had the following side effects: escherichia test positive, haemoglobin decreased, neutrophil count decreased, pain (What is pain?), pyrexia. Vidaza dosage: 220mg Days 1-4 + 15-18 Sq. During the same period patient was treated with TARCEVA (150mg Days 1-28 Po) (View Tarceva Review and Tarceva Label ), FENTANYL 75 (View Fentanyl-75 Review and Fentanyl-75 Label ), HYDROMORPHONE (View Hydromorphone Review and Hydromorphone Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), KC1 (View Kc1 Review and Kc1 Label ), FONDAPARINUX SODIUM (View Fondaparinux Sodium Review and Fondaparinux Sodium Label ). Patient was hospitalized.

6819918-5 | Acute Myeloid Leukaemia, Myelodysplastic Syndrome Transformation, Neutropenia, Pneumonia, Sepsis
Patient was taking Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: acute myeloid leukaemia, myelodysplastic syndrome transformation, neutropenia, pneumonia (What is pneumonia?), sepsis (What is sepsis?) on Jun 25, 2010 from CANADA Additional patient health information: Male patient , 71 years of age, . Vidaza dosage: . Patient was hospitalized.

6819254-7 |
Adverse event was reported on Jun 30, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with prophylaxis and. Location: GERMANY , 57 years of age, . During the same period patient was treated with RED BLOOD CELLS (6 Units) (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYCOTICS (View Antimycotics Review and Antimycotics Label ).

6819240-7 | Injection Site Pain, Nausea, Thrombocytopenia
on Jun 30, 2010 Male patient from GERMANY , 82 years of age, was treated with Vidaza (View Usage). Patient had the following side effects: injection site pain, nausea (What is nausea?), thrombocytopenia. Vidaza dosage: . During the same period patient was treated with PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).

6819231-6 | Acute Myeloid Leukaemia, Disease Progression, Injection Site Pain
on Jun 30, 2010 Male patient from GERMANY , 61 years of age, was diagnosed with prophylaxis and was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: acute myeloid leukaemia, disease progression, injection site pain. Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMIKOTICS (View Antimikotics Review and Antimikotics Label ).

6817556-1 | Acute Myeloid Leukaemia, Injection Site Reaction, Myelodysplastic Syndrome Transformation, Nausea
Patient was taking Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, injection site reaction, myelodysplastic syndrome transformation, nausea (What is nausea?) on Jun 29, 2010 from GERMANY Additional patient health information: Male patient , 68 years of age, . Vidaza dosage: .

6817094-6 | Sepsis
Adverse event was reported on Jun 28, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) . Location: GERMANY , 72 years of age, weighting 160.9 lb, Patient had the following side effects: sepsis (What is sepsis?). During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), HYDROXYUREA (View Hydroxyurea Review and Hydroxyurea Label ).

6812299-2 | Acute Myeloid Leukaemia, Myelodysplastic Syndrome Transformation, Neutropenia, Pneumonia, Sepsis
on Jun 25, 2010 Male patient from CANADA , 71 years of age, was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: acute myeloid leukaemia, myelodysplastic syndrome transformation, neutropenia, pneumonia (What is pneumonia?), sepsis (What is sepsis?). Vidaza dosage: . Patient was hospitalized.

6803622-3 | Pulmonary Fibrosis, Weight Decreased
on Jun 15, 2010 Male patient from GERMANY , 63 years of age, weighting 176.4 lb, was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary fibrosis (What is pulmonary fibrosis?), weight decreased. Vidaza dosage: . During the same period patient was treated with METOPROLOL SUCCINATE (1/2xday) (View Metoprolol Succinate Review and Metoprolol Succinate Label ), LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (View Losartan Potassium And Hydrochlorothiazide Review and Losartan Potassium And Hydrochlorothiazide Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), RASILEZ (View Rasilez Review and Rasilez Label ), ARIXTRA (View Arixtra Review and Arixtra Label ).

6803063-9 | Cardiac Failure
Patient was taking Vidaza (View Usage). Patient had the following side effects: cardiac failure on Jun 17, 2010 from GERMANY Additional patient health information: Male patient , 74 years of age, weighting 163.1 lb, was diagnosed with myelodysplastic syndrome and. Vidaza dosage: . Patient was hospitalized and became disabled.

6801260-X | Lung Disorder
Adverse event was reported on Jun 23, 2010 by a Female patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with epilepsy (What is epilepsy?) and. Location: FRANCE , weighting 114.6 lb, After Vidaza was administered, patient had the following side effects: lung disorder. During the same period patient was treated with REVLIMID (View Revlimid Review and Revlimid Label ), TEGRETOL (View Tegretol Review and Tegretol Label ), PIASCLEDINE (View Piascledine Review and Piascledine Label ), KARDEGIC (View Kardegic Review and Kardegic Label ), OROCAL (View Orocal Review and Orocal Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ). Patient was hospitalized.

6801083-1 | Acute Myeloid Leukaemia, Myelodysplastic Syndrome Transformation
on Jun 17, 2010 Male patient from GERMANY , 59 years of age, was diagnosed with prophylaxis and was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, myelodysplastic syndrome transformation. Vidaza dosage: . During the same period patient was treated with PLATELETS, CONCENTRATED (View Platelets, Concentrated Review and Platelets, Concentrated Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYCOTICS (View Antimycotics Review and Antimycotics Label ).

6801003-X | Anaemia, Infection, Injection Site Pain, Neutropenia, Thrombocytopenia
on Jun 23, 2010 Male patient from GERMANY , 66 years of age, was diagnosed with myelodysplastic syndrome, antibiotic prophylaxis and was treated with Vidaza (View Usage). Patient had the following side effects: anaemia, infection (What is infection?), injection site pain, neutropenia, thrombocytopenia. Vidaza dosage: . During the same period patient was treated with THROMBOCYTE CONCENTRATES (View Thrombocyte Concentrates Review and Thrombocyte Concentrates Label ), RED BLOOD CELLS (Concentrates) (View Red Blood Cells Review and Red Blood Cells Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6800804-1 | Sepsis
Patient was taking Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: sepsis (What is sepsis?) on Jun 23, 2010 from GERMANY Additional patient health information: Male patient , 72 years of age, weighting 160.9 lb, . Vidaza dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), HYDROXYUREA (View Hydroxyurea Review and Hydroxyurea Label ).

6795760-9 | Cardiac Failure, Cognitive Disorder, Haemorrhage, Head Injury
Adverse event was reported on Jun 21, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with myelodysplastic syndrome, gastric ulcer, hypertension, insomnia and. Location: SPAIN , 78 years of age, Patient experienced the following unwanted or unexpected effects: cardiac failure, cognitive disorder, haemorrhage, head injury. During the same period patient was treated with FILGRASTIM (View Filgrastim Review and Filgrastim Label ), RABEPRAZOLE SODIUM (View Rabeprazole Sodium Review and Rabeprazole Sodium Label ), BENAZEPRIL HYDROCHLORIDE (View Benazepril Hydrochloride Review and Benazepril Hydrochloride Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), EPLERENONE (View Eplerenone Review and Eplerenone Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ). Patient was hospitalized.

6790815-7 | Cardiac Failure, Pneumonia, Sepsis
on Jun 20, 2010 Male patient from GERMANY , 72 years of age, weighting 143.3 lb, was diagnosed with iron overload and was treated with Vidaza (View Usage). Patient had the following side effects: cardiac failure, pneumonia (What is pneumonia?), sepsis (What is sepsis?). Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS (View Platelets Review and Platelets Label ), EXJADE (View Exjade Review and Exjade Label ).

6790139-8 | Anaemia, Infection, Neutropenia, Thrombocytopenia
on Jun 17, 2010 Female patient from GERMANY , 72 years of age, was diagnosed with acute myeloid leukaemia, prophylaxis and was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: anaemia, infection (What is infection?), neutropenia, thrombocytopenia. Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYKOTICS (View Antimykotics Review and Antimykotics Label ).

6785776-0 | Anaemia, Neutropenia, Thrombocytopenia
Patient was taking Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, neutropenia, thrombocytopenia on Jun 17, 2010 from GERMANY Additional patient health information: Male patient , 65 years of age, was diagnosed with prophylaxis and. Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), ANTIMYCOTICS (View Antimycotics Review and Antimycotics Label ).

6784078-6 |
Adverse event was reported on Jun 17, 2010 by a Female patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with prophylaxis and. Location: GERMANY , 72 years of age, . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS (View Platelets Review and Platelets Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6783489-2 | Infarction
on Jun 10, 2010 Male patient from GERMANY , 76 years of age, was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: infarction. Vidaza dosage: .

6781952-1 |
on Jun 03, 2010 Male patient from SPAIN , 74 years of age, was diagnosed with chronic myelomonocytic leukaemia and was treated with Vidaza (View Usage). . Vidaza dosage: X5 Days (total Cycles 9), Injection. During the same period patient was treated with HYDREA (View Hydrea Review and Hydrea Label ).

6781508-0 |
Patient was taking Vidaza (View Usage). on Jun 17, 2010 from GERMANY Additional patient health information: Female patient , 72 years of age, . Vidaza dosage: . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ).

6781483-9 |
Adverse event was reported on Jun 15, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with iron overload and. Location: GERMANY , 72 years of age, . During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS (View Platelets Review and Platelets Label ), DEFERASIROX (View Deferasirox Review and Deferasirox Label ).

6779467-X | Pleural Effusion
on Jun 09, 2010 Male patient from FRANCE , 59 years of age, was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: pleural effusion. Vidaza dosage: .

6771941-5 | Cerebral Haemorrhage, Neuropathy Peripheral
on Jun 11, 2010 Male patient from FRANCE , 63 years of age, was treated with Vidaza (View Usage). Patient had the following side effects: cerebral haemorrhage, neuropathy peripheral. Vidaza dosage: . During the same period patient was treated with REVLIMID (View Revlimid Review and Revlimid Label ).

6771645-9 | Febrile Neutropenia, Haematoma, Pneumonia, Thrombocytosis, Vomiting
Patient was taking Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: febrile neutropenia, haematoma, pneumonia (What is pneumonia?), thrombocytosis, vomiting on Jun 02, 2010 from SPAIN Additional patient health information: Male patient , 71 years of age, . Vidaza dosage: . During the same period patient was treated with ANTI DIABETICS (View Anti-diabetics Review and Anti-diabetics Label ). Patient was hospitalized.

6770306-X | Pneumonia Fungal
Adverse event was reported on Jun 09, 2010 by a Male patient taking Vidaza (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia and. Location: SWITZERLAND , 74 years of age, Patient experienced the following unwanted or unexpected effects: pneumonia fungal. During the same period patient was treated with PANTOZOL (View Pantozol Review and Pantozol Label ), JANUMET (500/50 Mg) (View Janumet Review and Janumet Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), ZYLORIC (View Zyloric Review and Zyloric Label ), VALTREX (View Valtrex Review and Valtrex Label ), BACTRIM (View Bactrim Review and Bactrim Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), PASPERTIN (View Paspertin Review and Paspertin Label ). Patient was hospitalized.

6770210-7 | Infarction
on Jun 10, 2010 Female patient from GERMANY , 75 years of age, was treated with Vidaza (View Usage). Patient had the following side effects: infarction. Vidaza dosage: .

6770103-5 | Sigmoiditis
on Jun 03, 2010 Male patient from FRANCE , weighting 177.5 lb, was diagnosed with myelodysplastic syndrome, hypertension, thrombosis prophylaxis, reflux gastritis and was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: sigmoiditis. Vidaza dosage: . During the same period patient was treated with NEO RECORMON (View Neo Recormon Review and Neo Recormon Label ), LASIX (View Lasix Review and Lasix Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), KARDEGIC (View Kardegic Review and Kardegic Label ), INIPOMP (View Inipomp Review and Inipomp Label ). Patient was hospitalized.

6764525-6 | Dermatitis Exfoliative
Patient was taking Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: dermatitis exfoliative on May 28, 2010 from NETHERLANDS Additional patient health information: Male patient , weighting 198.4 lb, was diagnosed with myelodysplastic syndrome and. Vidaza dosage: . During the same period patient was treated with COTRIM (View Cotrim Review and Cotrim Label ), MOVICOLON (View Movicolon Review and Movicolon Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), AMITRIPTYLINE (View Amitriptyline Review and Amitriptyline Label ), COVERSYL (View Coversyl Review and Coversyl Label ). Patient was hospitalized.

6763621-7 | Blood Creatinine Increased, Leukocytosis
Adverse event was reported on May 27, 2010 by a Female patient taking Vidaza (View Usage) (Dosage: ) . Location: SPAIN , 73 years of age, Patient had the following side effects: blood creatinine increased, leukocytosis. During the same period patient was treated with SALBUTAMOL (View Salbutamol Review and Salbutamol Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), COLCHICINE (View Colchicine Review and Colchicine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ). Patient was hospitalized.

6763491-7 | Acute Myeloid Leukaemia, Myelodysplastic Syndrome Transformation, Neutropenia, Pneumonia, Sepsis
on Jun 03, 2010 Male patient from CANADA , 71 years of age, was treated with Vidaza (View Usage). After Vidaza was administered, patient had the following side effects: acute myeloid leukaemia, myelodysplastic syndrome transformation, neutropenia, pneumonia (What is pneumonia?), sepsis (What is sepsis?). Vidaza dosage: . Patient was hospitalized.

6761956-5 | Cellulitis, Injection Site Nodule, Soft Tissue Necrosis
on Jun 03, 2010 Female patient from FRANCE , 70 years of age, was treated with Vidaza (View Usage). Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), injection site nodule, soft tissue necrosis. Vidaza dosage: .

6760690-5 | Disease Progression, Petechiae, Pyrexia
Patient was taking Vidaza (View Usage). Patient had the following side effects: disease progression, petechiae, pyrexia on May 26, 2010 from SPAIN Additional patient health information: Female patient , 69 years of age, weighting 141.1 lb, was diagnosed with acute myeloid leukaemia and. Vidaza dosage: . Patient was hospitalized.